Medtronic Minimed Overnight Closed-Loop System
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01881009|
Recruitment Status : Completed
First Posted : June 19, 2013
Last Update Posted : March 9, 2015
To test the function and safety of the Medtronic Overnight Closed Loop (OCL) System in a closely monitored 12 hour overnight inpatient study. Once the safety of the device has been validated we will move the study to an outpatient diabetes camp setting. The camp setting will allow us to obtain pilot efficacy and safety data in a "real-life" environment.
We plan to compare the subject control nights to the subject nights on the OCL system to assess the percent of sensor glucose readings in the target range of 70-150 mg/dl. Based on previous research, we anticipate that the use of the OCL system will contribute to a greater percentage of sensor glucose readings in the target range.
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes Mellitus Autoimmune Diabetes Juvenile-Onset Diabetes Diabetes, Mellitus, Type 1||Device: ePID Algorithm on an Android Platform with Remote Monitoring||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||46 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Nocturnal Closed-Loop Control Using An ePID (Enhanced Proportional Integral Derivative) Algorithm On An Android Platform With Remote Monitoring In A Closely Monitored Camp Setting: The OCL Camp Study|
|Study Start Date :||June 2013|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
Experimental: Overnight Closed Loop Control (OCL)
Overnight Closed Loop Control with Remote Monitoring using the ePID Algorithm on an Android Platform with Remote Monitoring
Device: ePID Algorithm on an Android Platform with Remote Monitoring
Medtronic Overnight Closed-Loop System: Revel insulin pump, Enlite sensor, Minimed transmitter, ePID algorithm on an Android platform with remote monitoring.
No Intervention: Control Nights
Sensor augmented pump without OCL (overnight closed loop) or remote monitoring
- Target sensor glucose 70-150 mg/dl [ Time Frame: Approximately 12 hours ]Compared to control nights, the percent of sensor glucose readings in the target range of 70-150 mg/dl.
- Percentage of time CGM glucose readings are <70 mg/dl and > 180 mg/dl [ Time Frame: Approximately 12 hours ]
Secondary measures of glucose efficacy comparing treatment to control nights:
- Percentage of time CGM glucose readings are <70 mg/dl and > 180 mg/dl
- Distribution of CGM and meter glucose values overnight. (min, max, median, interquartile ranges, mean, standard deviation)
- Hypoglycemia area under the curve (AUC) (CGM glucose less than 60 mg/dL, 70 mg/dL,)
- Hyperglycemia AUC (CGM glucose greater than 180 mg/dL, 240 mg/dl)
- Incidence of hypoglycemia (meter glucose less than 60 mg/dL, less than 70 mg/dL)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01881009
|United States, California|
|Stanford, California, United States, 94305-5208|
|Principal Investigator:||Bruce Buckingham, MD||Stanford University|